USRE29588E - Preparation of d-2-amino-1-butanol salts - Google Patents
Preparation of d-2-amino-1-butanol salts Download PDFInfo
- Publication number
- USRE29588E USRE29588E US05/204,377 US20437771A USRE29588E US RE29588 E USRE29588 E US RE29588E US 20437771 A US20437771 A US 20437771A US RE29588 E USRE29588 E US RE29588E
- Authority
- US
- United States
- Prior art keywords
- butanol
- amino
- tartrate
- acid
- water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000002360 preparation method Methods 0.000 title claims description 3
- JCBPETKZIGVZRE-SCSAIBSYSA-N (2r)-2-aminobutan-1-ol Chemical class CC[C@@H](N)CO JCBPETKZIGVZRE-SCSAIBSYSA-N 0.000 title abstract description 11
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims abstract description 60
- JCBPETKZIGVZRE-BYPYZUCNSA-N (2s)-2-aminobutan-1-ol Chemical compound CC[C@H](N)CO JCBPETKZIGVZRE-BYPYZUCNSA-N 0.000 claims abstract description 41
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims abstract description 36
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 31
- JCBPETKZIGVZRE-UHFFFAOYSA-N 2-aminobutan-1-ol Chemical compound CCC(N)CO JCBPETKZIGVZRE-UHFFFAOYSA-N 0.000 claims abstract description 24
- 239000002904 solvent Substances 0.000 claims abstract description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 23
- 239000000203 mixture Substances 0.000 claims abstract description 16
- 238000000926 separation method Methods 0.000 claims abstract description 6
- 239000002253 acid Substances 0.000 claims description 30
- 238000000034 method Methods 0.000 claims description 25
- FEWJPZIEWOKRBE-JCYAYHJZSA-L L-tartrate(2-) Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-L 0.000 claims description 24
- 150000003892 tartrate salts Chemical class 0.000 claims description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 4
- 229910000287 alkaline earth metal oxide Inorganic materials 0.000 claims description 4
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 claims description 3
- 238000001704 evaporation Methods 0.000 claims description 2
- 238000001640 fractional crystallisation Methods 0.000 claims description 2
- UVRLVWTYHIFQPQ-IISSFJTQSA-N 4-[(2R)-2-aminobutoxy]-2,3-dihydroxy-4-oxobutanoic acid Chemical compound CC[C@@H](N)COC(=O)C(O)C(O)C(O)=O UVRLVWTYHIFQPQ-IISSFJTQSA-N 0.000 claims 2
- UVRLVWTYHIFQPQ-KXGSVCODSA-N 4-[(2S)-2-aminobutoxy]-2,3-dihydroxy-4-oxobutanoic acid Chemical compound CC[C@H](N)COC(=O)C(O)C(O)C(O)=O UVRLVWTYHIFQPQ-KXGSVCODSA-N 0.000 claims 2
- AUAHHJJRFHRVPV-BZDVOYDHSA-N ethambutol dihydrochloride Chemical compound [Cl-].[Cl-].CC[C@@H](CO)[NH2+]CC[NH2+][C@@H](CC)CO AUAHHJJRFHRVPV-BZDVOYDHSA-N 0.000 claims 1
- 150000003839 salts Chemical class 0.000 abstract description 14
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 abstract description 7
- 239000001358 L(+)-tartaric acid Substances 0.000 abstract description 3
- 235000011002 L(+)-tartaric acid Nutrition 0.000 abstract description 3
- FEWJPZIEWOKRBE-LWMBPPNESA-N L-(+)-Tartaric acid Natural products OC(=O)[C@@H](O)[C@H](O)C(O)=O FEWJPZIEWOKRBE-LWMBPPNESA-N 0.000 abstract description 3
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 abstract description 3
- 239000000920 calcium hydroxide Substances 0.000 abstract description 3
- 229910001861 calcium hydroxide Inorganic materials 0.000 abstract description 3
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 17
- 235000019441 ethanol Nutrition 0.000 description 10
- 238000001914 filtration Methods 0.000 description 9
- 239000002585 base Substances 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 5
- AEUTYOVWOVBAKS-UWVGGRQHSA-N ethambutol Chemical compound CC[C@@H](CO)NCCN[C@@H](CC)CO AEUTYOVWOVBAKS-UWVGGRQHSA-N 0.000 description 5
- 238000002844 melting Methods 0.000 description 5
- 230000008018 melting Effects 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 235000002906 tartaric acid Nutrition 0.000 description 4
- 239000011975 tartaric acid Substances 0.000 description 4
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 3
- AEUTYOVWOVBAKS-UHFFFAOYSA-N 2-[2-(1-hydroxybutan-2-ylamino)ethylamino]-1-butanol Chemical class CCC(CO)NCCNC(CC)CO AEUTYOVWOVBAKS-UHFFFAOYSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 239000012452 mother liquor Substances 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 238000001953 recrystallisation Methods 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- UUDLQDCYDSATCH-ZVGUSBNCSA-N (2r,3r)-2,3-dihydroxybutanedioic acid;hydrate Chemical compound O.OC(=O)[C@H](O)[C@@H](O)C(O)=O UUDLQDCYDSATCH-ZVGUSBNCSA-N 0.000 description 2
- LZDKZFUFMNSQCJ-UHFFFAOYSA-N 1,2-diethoxyethane Chemical compound CCOCCOCC LZDKZFUFMNSQCJ-UHFFFAOYSA-N 0.000 description 2
- RRQYJINTUHWNHW-UHFFFAOYSA-N 1-ethoxy-2-(2-ethoxyethoxy)ethane Chemical compound CCOCCOCCOCC RRQYJINTUHWNHW-UHFFFAOYSA-N 0.000 description 2
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 2
- ZNQVEEAIQZEUHB-UHFFFAOYSA-N 2-ethoxyethanol Chemical compound CCOCCO ZNQVEEAIQZEUHB-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- -1 aliphatic alcohols Chemical class 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- QVQLCTNNEUAWMS-UHFFFAOYSA-N barium oxide Chemical compound [Ba]=O QVQLCTNNEUAWMS-UHFFFAOYSA-N 0.000 description 2
- GUPPESBEIQALOS-UHFFFAOYSA-L calcium tartrate Chemical compound [Ca+2].[O-]C(=O)C(O)C(O)C([O-])=O GUPPESBEIQALOS-UHFFFAOYSA-L 0.000 description 2
- 239000001427 calcium tartrate Substances 0.000 description 2
- 235000011035 calcium tartrate Nutrition 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 150000004985 diamines Chemical class 0.000 description 2
- SBZXBUIDTXKZTM-UHFFFAOYSA-N diglyme Chemical compound COCCOCCOC SBZXBUIDTXKZTM-UHFFFAOYSA-N 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 229960000285 ethambutol Drugs 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000010899 nucleation Methods 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- IATRAKWUXMZMIY-UHFFFAOYSA-N strontium oxide Chemical compound [O-2].[Sr+2] IATRAKWUXMZMIY-UHFFFAOYSA-N 0.000 description 2
- PAAZPARNPHGIKF-UHFFFAOYSA-N 1,2-dibromoethane Chemical compound BrCCBr PAAZPARNPHGIKF-UHFFFAOYSA-N 0.000 description 1
- DURPTKYDGMDSBL-UHFFFAOYSA-N 1-butoxybutane Chemical compound CCCCOCCCC DURPTKYDGMDSBL-UHFFFAOYSA-N 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 101100386054 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) CYS3 gene Proteins 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- RQPZNWPYLFFXCP-UHFFFAOYSA-L barium dihydroxide Chemical compound [OH-].[OH-].[Ba+2] RQPZNWPYLFFXCP-UHFFFAOYSA-L 0.000 description 1
- 229910001863 barium hydroxide Inorganic materials 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- BRPQOXSCLDDYGP-UHFFFAOYSA-N calcium oxide Chemical compound [O-2].[Ca+2] BRPQOXSCLDDYGP-UHFFFAOYSA-N 0.000 description 1
- 239000000292 calcium oxide Substances 0.000 description 1
- ODINCKMPIJJUCX-UHFFFAOYSA-N calcium oxide Inorganic materials [Ca]=O ODINCKMPIJJUCX-UHFFFAOYSA-N 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000012433 hydrogen halide Substances 0.000 description 1
- 229910000039 hydrogen halide Inorganic materials 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229960003350 isoniazid Drugs 0.000 description 1
- QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000003791 organic solvent mixture Substances 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 239000010865 sewage Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 101150035983 str1 gene Proteins 0.000 description 1
- UUCCCPNEFXQJEL-UHFFFAOYSA-L strontium dihydroxide Chemical compound [OH-].[OH-].[Sr+2] UUCCCPNEFXQJEL-UHFFFAOYSA-L 0.000 description 1
- 229910001866 strontium hydroxide Inorganic materials 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
- C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
- C07C215/08—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with only one hydroxy group and one amino group bound to the carbon skeleton
Definitions
- This invention relates to a process for isolating (or separating) d-2-amino-1-butanol from a mixture of d-2-amino butanol and l-2-amino butanol by resolving the optical isomers using L-tartaric acid.
- 2-AMINO-1-BUTANOL IS USED AS AN INTERMEDIATE IN THE SYNTHESIS OF CERTAIN COMPOUNDS HAVING THERAPEUTIC ACTIVITY AS DESCRIBED IN U.S. Pat. No. 3,176,040, Mar. 30, 1965, Wilkinson and Shephard, Novel 2,2'-(Ethylenediimino)-Di-1-Butanols. .Iadd.
- N-( ⁇ -aminoalkyl)- ⁇ -aminoethanol derivatives symmetrically substituted on the two nitrogen atoms are desired
- the interaction of an ethylene dihalide with two equivalents of a ⁇ -(lower alkyl)- ⁇ -aminoethanol may conveniently be employed.
- the reaction is carried out without a solvent since both of the reactants are liquids.
- the reaction may, if desired, be carried out in an inert solvent.
- An inorganic base such as magnesium oxide or calcium carbonate or a two-fold stoichiometric excess of the aminoethanol may be employed as an acid acceptor of the hydrogen halide formed during the reaction.
- the reaction is carried out over a period of time ranging from 10 minutes to 48 hours, and at a temperature ranging from room temperature to the reflux temperature of the reaction mixture.
- the highly active (+)-isomer was prepared by brief heating of ethylene dichloride with excess (+)-2-amino-1-butanol.
- a 42% yield of purified (+)-2,2'-(ethylenediimino)-di-1-butanol (m.p. base 87.5°-88.8°, m.p. dihydrochloride 198.5°-200.3°) was obtained after removal of the less soluble meso isomer (m.p. base 135.8°-136.5°; m.p. dihydrochloride 203.5°-204.6°) corresponding to approximately the amount of levo impurity in the (+)-2-amino-1-butanol.
- the levo diamine m.p.
- the second carbon atom is asymmetric, there are two optically active isomers: (1) the dextro-form (d- or (+)-form), which rotates the plane of polarized light to the right, and (2) the levo-form (l- or (-)-form), which rotates the plane of polarized light to the left.
- the two forms are present in equal amounts in the racemic or unresolved mixture, i.e., dl-form, of 2-amino-1-butanol, which is the form of the commercial product.
- Optically active isomers cannot be separated by simple conventional procedures, such as ordinary crystallization.
- the most frequently used method for the separation of optically active isomers is chemical resolution.
- an optically active acid is added and the two resulting salts are separated by fractional crystallization. Repeated crystallizations are generally required to completely separate the two salts. After the salts are separated, the optically active free bases are recovered by adding a strong alkali to each.
- optical isomers are distinguished by absolute prefixes D- and L-. These symbols are used where the molecular configuration is known, often through synthesis from another molecule of established configuration. The optical rotation is then sometimes indicated by an additional symbol, usually (+) or (-).
- Tartaric acid is commercially available as a by-product of the wine industry in the L(+) tartaric acid form. This material actually has the L configuration but is dextro-rotatory and, therefore, indicated as (+).
- Other optically active acids such as glutamic acid have also been used commercially for resolution.
- L(+)-tartaric acid is added to an ethyl alcohol solution of dl-2-amino-1-butanol, and the acid salt of l-2-amino-1-butanol with the L-tartaric acid is crystallized from the solution.
- the alcohol was not anhydrous but contained water, probably about 5%.
- a low yield of impure salt of d-2-amino-1-butanol is recovered from the mother liquor.
- the solvent is the key to the process.
- the preferred solvent is methanol or ethanol, or a mixture.
- combinations of either or both with other volatile solvents are useful.
- the other solvents can be lower alcohols such as isopropyl, n-propanol, n-butanol, secondary butanol, etc., lower ether-alcohols such as methoxyethanol, ethoxyethanol, etc., lower ethers such as ethyl ether, isopropyl ether, butyl ether, 1,2-dimethoxyethane, 1,2-diethoxyethane, bis(methoxyethyl) ether, bis(ethoxyethyl) ether, etc., and lower ketones such as acetone, methyl ethyl ketone, etc. In the combinations at least 50% of methanol or ethanol should be present.
- the solvents should be anhydrous, up to about 1% of water based on the weight of the solvents can be tolerated.
- L-tartaric acid used depends on which of two procedures are employed. In the first procedure, between 0.75 and 1.0 mole of L-tartaric acid is used per mole of 2-amino-1-butanol. In the second procedure, about 0.5 mole of L-tartaric acid and about 0.5 mole of another acid which forms a salt soluble in the solvent system, such as formic, acetic, propionic, hydrochloric or hydrobromic acids, are used per mole of dl-2-amino-1-butanol.
- first procedure between 0.75 and 1.0 mole of L-tartaric acid is used per mole of 2-amino-1-butanol.
- another acid which forms a salt soluble in the solvent system such as formic, acetic, propionic, hydrochloric or hydrobromic acids
- the L-tartaric acid and dl-2-amino-1-butanol are dissolved in the solvent at an elevated temperature, usually at or near the reflux temperature. Sufficient solvent is used to effect solution.
- the solution is then cooled and the crystallized acid L-tartrate of d-2-amino-1-butanol is separated by filtering, centrifuging or a similar procedure.
- the salt is washed with a small amount of solvent, and if desired, may be purified by recrystallization. The excess of solvent may be removed from the crystals by drying, but for many uses this is unnecessary.
- the d-2-amino-1-butanol is recovered from the tartaric acid salt by adding an alkaline earth oxide or hydroxide to a suspension or solution of the salt in water, or mixture of water and water-miscible organic solvent, thereby freeing the d-2-amino-1-butanol as the organic base.
- Suitable alkaline earth oxides include barium oxide, calcium oxide and strontium oxide; suitable alkaline earth hydroxides include barium hydroxide, calcium hydroxide and strontium hydroxide.
- Suitable water-miscible solvents include lower aliphatic alcohols, such as methanol and ethanol, and amides such as dimethylformamide and formamide.
- Sufficient alkaline earth oxide and hydroxide is used to liberate all of the organic base from the L-tartrate; in other words, at least a stoichiometric amount of inorganic basic material is used.
- the alkaline earth L-tartrate is filtered from the solution of d-2-amino-1-butanol, and the latter is recovered by fractionally distilling the filtrate.
- the L-tartrate salt of l-2-amino-1-butanol remaining in the mother liquors after separation of the L-tartrate salt of d-2-amino-1-butanol can be recovered.
- 1.0 mole of L-tartaric acid per mole of dl-2-amino-1-butanol has been used, it is only necessary to add water and the salt crystallizes out as the monohydrate.
- less than 1.0 mole of L-tartaric acid has been used, sufficient tartaric acid is added to make a total of 1.0 mole per mole of dl-2-amino-1-butanol. Water is then added. The l-2-amino-1-butanol is then liberated from the L-tartrate as described above for the d-2-amino-1-butanol.
- the L-tartrate acid may be recovered from either or both components, and reused, thus conserving the optically active acid.
- the crystalline precipitate of the acid L-tartrate of d-2-amino-1-butanol is separated by filtration, washed with 45-50 parts of cold methanol and dried. About 60 parts, 81.5% of theory, of product is obtained.
- Example 2 The procedure of Example 1 is repeated substituting 47.5 parts (0.315 mole) of L-tartaric acid and 18.9 parts (0.315 mole) of glacial acetic acid for the 95 parts of L-tartaric acid. About 60 parts of acid L-tartrate of d-2-amino-1-butanol is obtained.
- the crystalline precipitate of the acid L-tartrate of d-2-amino-1-butanol is separated by filtration, washed with a minimum amount of a mixture of 2 parts of methanol and 1 part of isopropanol and dried. About 64 parts, 88% of theory, of product is obtained.
- Example 3 The procedure of Example 3 is repeated using 160 parts of dry methanol and 160 parts of dry acetone as the solvent. About 59 parts of the acid L-tartrate of d-2-amino-1-butanol is obtained.
- the combined tartaric acid salts from Examples 7 and 8 are mixed, acidified with a stoichiometric quantity of sulfuric acid, and sufficient water to dissolve all of the tartaric acid is added, the calcium sulfate is separated, and free L-tartaric acid recovered from the aqueous layer remaining, by evaporating off water.
- the L-tartaric acid is reused for a subsequent run.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
A racemic mixture of dl-2-amino-1-butanol is resolved with separation of the d-2-amino-1-butanol by crystallizing as a salt with L(+)-tartaric acid from an essentially anhydrous solution in ethanol or methanol. The salt is decomposed with calcium hydroxide to yield the d-2-amino-1-butanol. Water may be added to the residual anhydrous solution to separate the l-2-amino-1-butanol. Other listed volatile solvents may be present in the anhydrous ethanol or methanol without inhibiting the sharp separation.
Description
This invention relates to a process for isolating (or separating) d-2-amino-1-butanol from a mixture of d-2-amino butanol and l-2-amino butanol by resolving the optical isomers using L-tartaric acid.
2-AMINO-1-BUTANOL IS USED AS AN INTERMEDIATE IN THE SYNTHESIS OF CERTAIN COMPOUNDS HAVING THERAPEUTIC ACTIVITY AS DESCRIBED IN U.S. Pat. No. 3,176,040, Mar. 30, 1965, Wilkinson and Shephard, Novel 2,2'-(Ethylenediimino)-Di-1-Butanols. .Iadd.
This patent shows that the novel substituted N-(β-aminoalkyl)-amino-ethanes and their non-toxic acid-addition salts have been found to be highly useful in the treatment of tubercle bacilli infections when administered in amounts ranging from about 10 mg. to about 500 mg. per kilogram of body weight per day.
Where N-(β-aminoalkyl)-β-aminoethanol derivatives symmetrically substituted on the two nitrogen atoms are desired, the interaction of an ethylene dihalide with two equivalents of a β-(lower alkyl)-β-aminoethanol may conveniently be employed. Ordinarily, the reaction is carried out without a solvent since both of the reactants are liquids. However, the reaction may, if desired, be carried out in an inert solvent. An inorganic base such as magnesium oxide or calcium carbonate or a two-fold stoichiometric excess of the aminoethanol may be employed as an acid acceptor of the hydrogen halide formed during the reaction. The reaction is carried out over a period of time ranging from 10 minutes to 48 hours, and at a temperature ranging from room temperature to the reflux temperature of the reaction mixture.
To 227 g. (2.55 moles) of 2-amino-1-butanol was added 100 g. (1.0 mole) of ethylene dichloride. The mixture was heated to reflux and in a few minutes the exothermic reaction required the removal of exterior heating. After 10 minutes, exterior heating was recommended for an additional 20 minutes. The hot mixture was then poured into a flask, washing with and adding 300 ml. of methanol. To this was added cautiously 84 g. (2.1 moles) of sodium hydroxide in 80 ml. of water. The precipitated sodium chloride was removed by filtration. The excess 2-amino-1-butanol distilled as a light yellow oil at 83°-87° C./13 mm. The viscous residue distilled at 165°-170° C./0.6 mm. as a light yellow oil which tended to solidify in the air condenser; yield, 108 g. (58% of theory). Recrystallization by dissolving in 80 ml. of hot ethanol, adding about 150 ml. of petroleum ether (B.P. 90°-100° C.), and cooling at 5° C. overnight, gave 64 g. of white crystals melting at 128°-132.5° C. This, on recrystallization from 100 ml. of 95% ethanol, gave 35 g. of white crystals melting at 134.5°-136° C. and a second crop of 10 g. melting at 132.5°-134° C. (total yield 45 g., 22% of theory) which is the meso base. The dihydrochloride of this melts at 202°-203° C.
From the ethanolic filtrates on addition of 130 ml. of about 4 N ethanolic hydrochloric acid and cooling, there was obtained 55 g. of white crystals melting at 176.5°-178° C. and a second crop of 10 g. melting at 171.5°-174.5° C. This is the dl racemate dihydrochloride. .Iaddend.
For this synthesis, the d-form is preferred. Wilkinson, R. G. et al., J. Am. Chem. Soc 83, 2212-13 (1961).[...]..Iadd., show that the dextrorotatory form of 2,2'-(ethylenediimino)-di-1-butanol(ethambutol) is four times as active as streptomycin against an established infection with the human strain of Mycobacterium tuberculosis in mice. It is also fully active against isoniazid-resistant infection as well as against streptomycin-resistant infections in mice. The sharp stereo-specificity of the activity of this synthetic chemotherapeutic agent (dextro = 12 × meso = >200 × levo) contrasts with the equality in acute toxicity of the stereoisomers in mice.
The highly active (+)-isomer was prepared by brief heating of ethylene dichloride with excess (+)-2-amino-1-butanol. A 42% yield of purified (+)-2,2'-(ethylenediimino)-di-1-butanol (m.p. base 87.5°-88.8°, m.p. dihydrochloride 198.5°-200.3°) was obtained after removal of the less soluble meso isomer (m.p. base 135.8°-136.5°; m.p. dihydrochloride 203.5°-204.6°) corresponding to approximately the amount of levo impurity in the (+)-2-amino-1-butanol. The levo diamine (m.p. base 89°-90°; m.p. dihydrochloride 200.5°-201.5°) was prepared in the same way from (-)-2-amino-1-butanol in 52% yield. When (±)-2-amino-butanol reacted with either ethylene chloride, ethylene bromide or ditosyl glycol, the condensation occurred most rapidly at the temperature obtained without solvent, although a longer time at lower temperature (alcohol) has given comparable results. The main products, each isolated in about 40% yield, are the racemic base (m.p. 75°-76°; b.p. 160°-170° (0.3 mm.); dihydrochloride m.p. 179°-180°) and the meso diamine. .Iaddend.
The formula for 2-amino-1-butanol is: ##STR1##
As the second carbon atom is asymmetric, there are two optically active isomers: (1) the dextro-form (d- or (+)-form), which rotates the plane of polarized light to the right, and (2) the levo-form (l- or (-)-form), which rotates the plane of polarized light to the left. The two forms are present in equal amounts in the racemic or unresolved mixture, i.e., dl-form, of 2-amino-1-butanol, which is the form of the commercial product.
Optically active isomers cannot be separated by simple conventional procedures, such as ordinary crystallization. The most frequently used method for the separation of optically active isomers is chemical resolution. In the case of bases, an optically active acid is added and the two resulting salts are separated by fractional crystallization. Repeated crystallizations are generally required to completely separate the two salts. After the salts are separated, the optically active free bases are recovered by adding a strong alkali to each.
Some optical isomers are distinguished by absolute prefixes D- and L-. These symbols are used where the molecular configuration is known, often through synthesis from another molecule of established configuration. The optical rotation is then sometimes indicated by an additional symbol, usually (+) or (-).
Such a process requires an optically active material to be used in the resolution. Tartaric acid is commercially available as a by-product of the wine industry in the L(+) tartaric acid form. This material actually has the L configuration but is dextro-rotatory and, therefore, indicated as (+). Other optically active acids such as glutamic acid have also been used commercially for resolution.
In one procedure [Compt. Rend. 253, 2704 (1961)], L(+)-tartaric acid is added to an ethyl alcohol solution of dl-2-amino-1-butanol, and the acid salt of l-2-amino-1-butanol with the L-tartaric acid is crystallized from the solution. Presumably the alcohol was not anhydrous but contained water, probably about 5%. A low yield of impure salt of d-2-amino-1-butanol is recovered from the mother liquor.
In another procedure [J. Am. Chem. Soc. 76, 2801, 4382 (1954)], L-tartaric acid was treated in an aqueous solution with dl-2-amino-1-butanol, and the acid salt of l,2-amino-1-butanol with L-tartaric acid is crystallized from the solution. A low yield of impure salt of d-2-amino-1-butanol is recoverable from the mother liquor.
We have now found that superior resolution is obtained by dissolving dl-2-amino-1-butanol in a suitable essentially anhydrous organic solvent, then adding L(+)-tartaric acid. The acid L-tartrate of d-2-amino-1-butanol crystallizes from solution, leaving the l-2-amino-1-butanol in solution. The d-2-amino-1-butanol is then recovered by (1) dissolving or suspending the acid L-tartrate of d-2-amino-1-butanol in water or water-organic solvent mixture, (2) adding a strong alkaline earth alkali, (3) separating the inorganic tartrate salt by filtration, and (4) fractionally distilling the filtrate. An excellent yield of d-2-amino-1-butanol of high purity is thus obtained.
The solvent is the key to the process. The preferred solvent is methanol or ethanol, or a mixture. Also, combinations of either or both with other volatile solvents are useful. The other solvents can be lower alcohols such as isopropyl, n-propanol, n-butanol, secondary butanol, etc., lower ether-alcohols such as methoxyethanol, ethoxyethanol, etc., lower ethers such as ethyl ether, isopropyl ether, butyl ether, 1,2-dimethoxyethane, 1,2-diethoxyethane, bis(methoxyethyl) ether, bis(ethoxyethyl) ether, etc., and lower ketones such as acetone, methyl ethyl ketone, etc. In the combinations at least 50% of methanol or ethanol should be present.
Although for optimum results the solvents should be anhydrous, up to about 1% of water based on the weight of the solvents can be tolerated.
The amount of L-tartaric acid used depends on which of two procedures are employed. In the first procedure, between 0.75 and 1.0 mole of L-tartaric acid is used per mole of 2-amino-1-butanol. In the second procedure, about 0.5 mole of L-tartaric acid and about 0.5 mole of another acid which forms a salt soluble in the solvent system, such as formic, acetic, propionic, hydrochloric or hydrobromic acids, are used per mole of dl-2-amino-1-butanol.
The L-tartaric acid and dl-2-amino-1-butanol are dissolved in the solvent at an elevated temperature, usually at or near the reflux temperature. Sufficient solvent is used to effect solution. The solution is then cooled and the crystallized acid L-tartrate of d-2-amino-1-butanol is separated by filtering, centrifuging or a similar procedure. The salt is washed with a small amount of solvent, and if desired, may be purified by recrystallization. The excess of solvent may be removed from the crystals by drying, but for many uses this is unnecessary.
The d-2-amino-1-butanol is recovered from the tartaric acid salt by adding an alkaline earth oxide or hydroxide to a suspension or solution of the salt in water, or mixture of water and water-miscible organic solvent, thereby freeing the d-2-amino-1-butanol as the organic base.
Suitable alkaline earth oxides include barium oxide, calcium oxide and strontium oxide; suitable alkaline earth hydroxides include barium hydroxide, calcium hydroxide and strontium hydroxide.
Suitable water-miscible solvents include lower aliphatic alcohols, such as methanol and ethanol, and amides such as dimethylformamide and formamide.
Sufficient alkaline earth oxide and hydroxide is used to liberate all of the organic base from the L-tartrate; in other words, at least a stoichiometric amount of inorganic basic material is used.
The alkaline earth L-tartrate is filtered from the solution of d-2-amino-1-butanol, and the latter is recovered by fractionally distilling the filtrate.
The L-tartrate salt of l-2-amino-1-butanol remaining in the mother liquors after separation of the L-tartrate salt of d-2-amino-1-butanol can be recovered. When 1.0 mole of L-tartaric acid per mole of dl-2-amino-1-butanol has been used, it is only necessary to add water and the salt crystallizes out as the monohydrate. When less than 1.0 mole of L-tartaric acid has been used, sufficient tartaric acid is added to make a total of 1.0 mole per mole of dl-2-amino-1-butanol. Water is then added. The l-2-amino-1-butanol is then liberated from the L-tartrate as described above for the d-2-amino-1-butanol.
The L-tartrate acid may be recovered from either or both components, and reused, thus conserving the optically active acid.
As illustrative of this invention, certain examples here follow. Parts and percentages are by weight in the following examples and claims.
To a stirred solution of 55 parts (0.62 mole) of racemic 2-amino-1-butanol in 400 parts of methanol (0.03-0.04% water) there is slowly added 95 parts (0.63 mole) of L-tartartic acid while keeping the temperature of the solution at 35°-40° C. When all of the L-tartaric acid has dissolved, the solution is .[.seeded.]. .Iadd."seeded".Iaddend. with a trace amount of acid L-tartrate of d-2-amino-1-butanol at 30°-35° C. The mixture is cooled over three hours to a temperature of 5° C. The crystalline precipitate of the acid L-tartrate of d-2-amino-1-butanol is separated by filtration, washed with 45-50 parts of cold methanol and dried. About 60 parts, 81.5% of theory, of product is obtained.
The procedure of Example 1 is repeated substituting 47.5 parts (0.315 mole) of L-tartaric acid and 18.9 parts (0.315 mole) of glacial acetic acid for the 95 parts of L-tartaric acid. About 60 parts of acid L-tartrate of d-2-amino-1-butanol is obtained.
To a stirred solution of 55 parts (0.62 mole) of racemic 2-amino-1-butanol in a mixture of 280 parts of dry methanol and 120 parts of dry isopropanol, there is slowly added 75 parts (0.5 mole) of L-tartaric acid while keeping the temperature at 35°-40° C. When all of the L-tartaric acid has dissolved, a trace amount of crystalline acid L-tartrate of d-2-amino-1-butanol is added as seed, and the mixture is cooled to 0°-5° C. over two hours. The crystalline precipitate of the acid L-tartrate of d-2-amino-1-butanol is separated by filtration, washed with a minimum amount of a mixture of 2 parts of methanol and 1 part of isopropanol and dried. About 64 parts, 88% of theory, of product is obtained.
The procedure of Example 3 is repeated using 160 parts of dry methanol and 160 parts of dry acetone as the solvent. About 59 parts of the acid L-tartrate of d-2-amino-1-butanol is obtained.
In a similar manner, mixtures of dry methanol and each of methoxyethanol, ethoxyethanol, 1,2-dimethoxyethane, 1,2-diethoxyethane, bis(methoxyethyl) ether, bis(ethoxyethyl) ether and methyl ethyl ketone are employed. Similar results are obtained.
To a stirred solution of 55 parts (0.62 mole) of racemic 2-amino-1-butanol in 550 parts of anhydrous ethanol there is slowly added 75 parts (0.5 mole) of L-tartaric acid while keeping the temperature below 60° C. The mixture is then stirred at 60°-65° C. until all of the L-tartaric acid has dissolved. After "seeding" with a trace amount of acid L-tartrate of d-2-amino-1-butanol, the mixture is cooled to about 20° C. The crystalline precipitate of the acid L-tartrate of d-2-amino-1-butanol is separated by filtration, washed with anhydrous ethanol and dried. About 65 parts, 98% of theory, of product is obtained.
To a stirred solution of 89 parts (1.0 mole) of technical racemic 2-amino-1-butanol (92% real) in 280 parts of dry methanol there is slowly added 150 parts (1.0 mole) of L-tartaric acid while keeping the temperature at 40°-45° C. After seeding the resulting solution with a trace amount of acid L-tartrate of d-2-amino-1-butanol and cooling to 0°-5° C., over three hours, a crystalline precipitate of the acid L-tartrate of d-2-amino-1-butanol is formed, which is separated by filtration, washed with 120 parts of cold methanol and dried. About 107 parts, 89.2% of theory, of product is obtained.
The acid L-tartrate of d-2-amino-1-butanol, the product of Example 6, is dissolved in a minimum amount of water. Sufficient calcium hydroxide is added to precipitate all of the tartaric acid as calcium tartrate. The calcium tartrate is separated by filtration, and the d-2-amino-1-butanol is recovered as the free base by distilling the filtrate to separate the water, leaving the free base behind. A column is used to prevent the d-2-amino-1-butanol from distilling over in part with the water.
To the combined mother liquor and wash liquor from Example 6 there is added 55 parts of water at 35°-40° C. The solution is "seeded" with a trace amount of acid L-tartrate monohydrate of l-2-amino-1-butanol. After cooling to 5° C. over 2.5 hours, the crystalline product is separated by filtration, washed with a cold mixture of 80 parts of methanol and 20 parts of water and dried. About 98 parts, 76% of theory, of the acid L-tartrate monohydrate of l-2-amino-1-butanol is obtained.
Following the procedure of Example 7, the l-2-amino-1-butanol is separated.
The combined tartaric acid salts from Examples 7 and 8 are mixed, acidified with a stoichiometric quantity of sulfuric acid, and sufficient water to dissolve all of the tartaric acid is added, the calcium sulfate is separated, and free L-tartaric acid recovered from the aqueous layer remaining, by evaporating off water.
The L-tartaric acid is reused for a subsequent run.
In laboratory and small scale operations, after separation of the d-2-amino-1-butanol, as in Example 7, using the process of Example 2 for preparation of the tartaric acid salt, all residues of solvents, residual tartrates and l-2-amino-1-butanol can be combined and burned or dumped to sewage. In large scale operations, solvent recovery and L-tartaric acid recovery are economically justified.
Claims (7)
1. The process of preparing the acid L-tartrate of d-2-amino-1-butanol comprising forming a solution of dl-2-amino-1-butanol in a solvent consisting essentially of an anhydrous lower alkanol selected from the group consisting of methanol and ethanol and not more than 1.0% water, adding thereto L-tartaric acid in at least about a one-half molar quantity, and separating the crystalline acid L-tartrate of d-2-amino-1-butanol.
2. The process of claim 1 in which the solvent is essentially anhydrous methanol.
3. The process of claim 1 in which the solvent is essentially anhydrous ethanol.
4. The process of claim 1 in which the solvent is essentially an anhydrous mixture of ethanol and methanol.
5. A process for separating d-2-amino-1-butanol from dl-2-amino-1-butanol comprising following the process of claim 1, then suspending the acid L-tartrate salt of d-2-amino-1-butanol in a water-containing solvent, adding an alkaline earth oxide or hydroxide, separating the alkaline earth L-tartrate and fractionally distilling the remaining layer to obtain d-2-amino-1-butanol.
6. The process of claim 5 in which the separation of the tartrate salt is conducted in water.
7. The process of claim 6 in which about a stoichiometric quantity of sulfuric acid and sufficient water to dissolve the L-tartaric acid is added to the alkaline earth L-tartrate, the calcium sulfate formed is separated out and free L-tartaric acid is recovered by evaporating off the water. .Iadd. 8. In the preparation of the (+)2,2'-(ethylenediimino) di-1-butanol dihydrochloride, the improvement comprising the process of preparing the acid L-tartrate of d-2-amino-1-butanol comprising forming a solution of dl-2-amino-1-butanol in a solvent consisting essentially of an anhydrous lower alkanol selected from the group consisting of methanol and ethanol and not more than 1.0% water, adding thereto L-tartaric acid in at least about a one-half molar quantity, and separating the crystalline acid L-tartrate of d-2-amino-1-butanol. .Iaddend. .Iadd. 9. In the process of preparing d-2-amino-1-butanol from dl-2-amino-1-butanol, the step which comprises separating d-2-amino-1-butanol (+) hydrogen tartrate from l-2-amino-1-butanol (+) hydrogen tartrate by fractional crystallization in anhydrous methyl alcohol in which the d-2-amino-1-butanol (+) hydrogen tartrate is comparatively insoluble and the anhydrous l-2-amino-1-butanol (+) hydrogen tartrate is very soluble. .Iaddend.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US57984266A | 1966-09-16 | 1966-09-16 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US57984266A Reissue | 1966-09-16 | 1966-09-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
USRE29588E true USRE29588E (en) | 1978-03-21 |
Family
ID=24318573
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US579842A Expired - Lifetime US3553257A (en) | 1966-09-16 | 1966-09-16 | Preparation of d-2-amino-1-butanol salts |
US05/204,377 Expired - Lifetime USRE29588E (en) | 1966-09-16 | 1971-12-02 | Preparation of d-2-amino-1-butanol salts |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US579842A Expired - Lifetime US3553257A (en) | 1966-09-16 | 1966-09-16 | Preparation of d-2-amino-1-butanol salts |
Country Status (2)
Country | Link |
---|---|
US (2) | US3553257A (en) |
GB (1) | GB1188185A (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050113574A1 (en) * | 2003-09-05 | 2005-05-26 | Elena Bogatcheva | Methods and compositions comprising diamines as new anti-tubercular therapeutics |
US20060020041A1 (en) * | 2002-05-17 | 2006-01-26 | Protopopova Marina N | Anti tubercular drug: compositions and methods |
US7456222B2 (en) | 2002-05-17 | 2008-11-25 | Sequella, Inc. | Anti tubercular drug: compositions and methods |
US20090281054A1 (en) * | 2008-05-06 | 2009-11-12 | Venkata Reddy | Compositions and methods comprising capuramycin analogues |
US7652039B2 (en) | 2002-05-17 | 2010-01-26 | Sequella, Inc. | Methods of use and compositions for the diagnosis and treatment of infectious disease |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5318006B2 (en) * | 1973-09-28 | 1978-06-13 | ||
US3944616A (en) * | 1974-10-29 | 1976-03-16 | American Cyanamid Company | Purification of d,d'-2,2'(ethylenediimino)di-1-butanol dihydrochloride |
US3944619A (en) * | 1976-02-20 | 1976-03-16 | American Cyanamid Company | Synthesis of d-2-amino-1-butanol |
US4082804A (en) * | 1976-10-28 | 1978-04-04 | Teijin Limited | Process for preparing 2-amino-1-butanol by reaction of the tartarate with an alkaline earth metal compound |
DE2933895A1 (en) * | 1979-08-22 | 1981-03-12 | Basf Ag, 6700 Ludwigshafen | METHOD FOR CLEAVING RACEMIC APPLE ACID. |
IT1208109B (en) * | 1983-11-23 | 1989-06-06 | Alfa Chem Ital | PROCEDURE FOR THE OPTICAL RESOLUTION OF ARYLPROPIONIC ACIDS |
US5763647A (en) * | 1990-03-30 | 1998-06-09 | Shionogi & Co., Ltd. | Preparation of optically active 1,4-bridged-cyclohexane carboxylic acid derivatives |
DE19505994C2 (en) * | 1995-02-21 | 1999-01-14 | Degussa | Process for the preparation of optically active tert-leucinol and its use |
JP4728548B2 (en) | 1999-09-07 | 2011-07-20 | 三菱レイヨン株式会社 | Method for producing optically active amino alcohol |
CN107245038A (en) * | 2016-07-19 | 2017-10-13 | 嘉兴润博化工科技有限公司 | A kind of method for splitting of amino butanol |
CN113277941A (en) * | 2021-05-14 | 2021-08-20 | 湖北新生源生物工程有限公司 | Method for recovering L-tartaric acid from D-cysteine conversion hydrolysate |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3116332A (en) * | 1958-10-17 | 1963-12-31 | Du Pont | Resolution of racemic aminoisopropanol |
US3401194A (en) * | 1963-08-10 | 1968-09-10 | Zoja Lab Chim Farm | Process for the resolution of stereoisomers from racemic 1-hydroxy-2-amino butane |
-
1966
- 1966-09-16 US US579842A patent/US3553257A/en not_active Expired - Lifetime
-
1967
- 1967-06-02 GB GB25698/67A patent/GB1188185A/en not_active Expired
-
1971
- 1971-12-02 US US05/204,377 patent/USRE29588E/en not_active Expired - Lifetime
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3116332A (en) * | 1958-10-17 | 1963-12-31 | Du Pont | Resolution of racemic aminoisopropanol |
US3401194A (en) * | 1963-08-10 | 1968-09-10 | Zoja Lab Chim Farm | Process for the resolution of stereoisomers from racemic 1-hydroxy-2-amino butane |
Non-Patent Citations (2)
Title |
---|
Radke et al.: JACS, vol. 76, pp. 2801-2802 (1954). * |
Roggero et al.: Compt. Rend, vol. 253, pp. 2704-2705 (1961). * |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110118307A1 (en) * | 2002-05-17 | 2011-05-19 | Marina Nikolaevna Protopopova | Compositions and methods for the treatment of infectious diseases |
US20060020041A1 (en) * | 2002-05-17 | 2006-01-26 | Protopopova Marina N | Anti tubercular drug: compositions and methods |
US7456222B2 (en) | 2002-05-17 | 2008-11-25 | Sequella, Inc. | Anti tubercular drug: compositions and methods |
US7652039B2 (en) | 2002-05-17 | 2010-01-26 | Sequella, Inc. | Methods of use and compositions for the diagnosis and treatment of infectious disease |
US20100273826A1 (en) * | 2002-05-17 | 2010-10-28 | Sequella, Inc. | Methods of use and compositions for the diagnosis and treatment of infectious diseases |
US7842729B2 (en) | 2002-05-17 | 2010-11-30 | The United States Of America As Represented By The Department Of Health And Human Services | Anti tubercular drug: compositions and methods |
US8198303B2 (en) | 2002-05-17 | 2012-06-12 | Sequella, Inc. | Methods of use and compositions for the diagnosis and treatment of infectious diseases |
US8268894B2 (en) | 2002-05-17 | 2012-09-18 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Compositions and methods for the treatment of infectious diseases |
US7884097B2 (en) | 2003-09-05 | 2011-02-08 | Sequella, Inc. | Methods and compositions comprising diamines as new anti-tubercular therapeutics |
US20050113574A1 (en) * | 2003-09-05 | 2005-05-26 | Elena Bogatcheva | Methods and compositions comprising diamines as new anti-tubercular therapeutics |
US20090192173A1 (en) * | 2005-07-01 | 2009-07-30 | Sequella, Inc. | Anti-tubercular drugs: compositions and methods |
US8202910B2 (en) | 2005-07-01 | 2012-06-19 | Sequella, Inc. | Compositions and methods for treatment of infectious disease |
US20090281054A1 (en) * | 2008-05-06 | 2009-11-12 | Venkata Reddy | Compositions and methods comprising capuramycin analogues |
Also Published As
Publication number | Publication date |
---|---|
US3553257A (en) | 1971-01-05 |
GB1188185A (en) | 1970-04-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
USRE29588E (en) | Preparation of d-2-amino-1-butanol salts | |
US2528267A (en) | Eobeet j | |
US4319040A (en) | Process for the production of optically active threo-3-(3,4-dihydroxyphenyl)serine | |
US4224457A (en) | Process for manufacturing optically active sulfur-containing carboxylic acid | |
US3028430A (en) | Process for the production of optically active isomers of amphetamine | |
US3579586A (en) | Process for the preparation of the dextrorotatory 2,2' - (ethylene-di-imino)-di-1-butanol | |
US3579587A (en) | Process for the preparation of the dextrorotatory 2,2' - (ethylene-di-imino)-di-1-butanol | |
US3936495A (en) | Purification process | |
US4340751A (en) | Method of optical resolution of (±)-2-amino-1-butanol and/or (±)-mandelic acid | |
US4328173A (en) | Resolution of D,L-cis and D,L-trans 2,2-dimethyl-3-(2,2-dihalovinyl)-cyclopropane-1-carboxylic acids and salts thereof | |
US4571424A (en) | Optical resolution of racemic femoxetine | |
US3398150A (en) | Certain 7-phenethylaminopropyltheophylline derivatives | |
US3086972A (en) | Aza-thiaxanthene derivatives | |
US3317560A (en) | Indol-3-yl alkylguanidine derivatives | |
US2243977A (en) | Process for the preparation of amino-alcohols | |
US2794025A (en) | Process of resolving amino acids of the proline type | |
US2793212A (en) | Substituted benzamidopiperidinopropanes | |
US4906622A (en) | Optically active 2-chloro-12-(3-dimethylamino-2-methyl-propyl)-12H-dibenzo[d.g] [1,3,6] dioxazocines and a process for the preparation thereof | |
US3541139A (en) | Resolution of racemic alpha-hydroxy-beta,beta-dimethyl-gamma- butyrolactone | |
US5087698A (en) | Process for the optical resolution of dropopizine | |
WO1985003932A1 (en) | Novel diastereomer salts of phenylalanine and n-acyl derivatives thereof and process for the separation of optically active phenylalanine and n-acyl derivatives thereof | |
US2848489A (en) | Preparation of alkaline-earth salts of pantothenic acid | |
US3378592A (en) | Process for the production of 3, 4-dihydroxybenzyloxyaminehydrobromide | |
US4226803A (en) | Process for production of optically active bases | |
US4824964A (en) | Method for preparing optically active N-acetylindoline-2-carboxylic acid |